Uso de nivolumab en pacientes con recaída postrasplante alogénico de progenitores hematopoyéticos en enfermedad de Hodgkin: reporte de dos casos clínicos / Treatment of Hodgkin disease relapse after allogeneic transplantation with nivolumab. Report of two cases
Rev. méd. Chile
;
149(10): 1507-1511, oct. 2021. ilus
Artigo
em Espanhol
| LILACS
| ID: biblio-1389364
ABSTRACT
Hodgkin's Lymphoma has a very good prognosis. In the unusually refractory patients allogeneic transplantation offers a chance of cure. The so-called checkpoint inhibitors, such as Nivolumab can play a relevant role in this type of patients. Their side effects and usefulness after allogeneic transplantation are under investigation. Relapse after allogeneic transplantation has an extremely poor prognosis. We report two patients with refractory Hodgkin's lymphoma who relapsed after an allogeneic transplant and who were successfully treated with Nivolumab.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Doença de Hodgkin
/
Transplante de Células-Tronco Hematopoéticas
Limite:
Humanos
Idioma:
Espanhol
Revista:
Rev. méd. Chile
Assunto da revista:
Medicina
Ano de publicação:
2021
Tipo de documento:
Artigo
País de afiliação:
Chile
Instituição/País de afiliação:
Universidad Finis Terrae/CL
Similares
MEDLINE
...
LILACS
LIS